share_log

RedHill Settles Movantik Patent Litigation With Aurobindo

RedHill Settles Movantik Patent Litigation With Aurobindo

Redhill Setting Movantik與Aurobindo提起專利訴訟
Benzinga Real-time News ·  2021/09/23 11:11
  • RedHill Biopharma Ltd (NASDAQ:RDHL) has announced a settlement and license agreement with Aurobindo Pharma USA Inc resolving their patent litigation in the U.S.
  • The litigation was related to Aurobindo's Abbreviated New Drug Application seeking approval by the FDA to market a generic version of Movantik (naloxegol).
  • RedHill acquired from AstraZeneca plc (NASDAQ:AZN) in April 2020 the global rights to Movantik, excluding Europe and Canada.
  • Under the settlement agreement terms, Aurobindo may not sell a generic version of Movantik in the U.S. until April 1, 2031.
  • Related: RedHill Unveils New Movantik Data For Opioid-Induced Constipation.
  • Price Action: RDHL stock is up 0.21% at $4.76 during the market session on the last check Thursday.
  • 紅山生物醫藥有限公司(納斯達克股票代碼:RDHL)宣佈與以下公司達成和解和許可協議Aurobindo Pharma USA Inc.解決他們在美國的專利訴訟。
  • 這起訴訟與Aurobindo的簡化新葯申請有關,該申請尋求FDA的批准,以銷售Movantik(納洛西戈)的仿製藥。
  • Redhill於2020年4月從阿斯利康(納斯達克股票代碼:AZN)手中收購了Movantik的全球使用權,不包括歐洲和加拿大。
  • 根據和解協議條款,Aurobindo在2031年4月1日之前可能不會在美國銷售仿製藥Movantik。
  • 相關: Redhill公司公佈治療阿片類藥物誘導便祕的新Movantik數據.
  • 價格行動:在週四最後一次檢查的市場時段,RDHL股價上漲0.21%,至4.76美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論